title: Active pulmonary tuberculosis: Role for amikacin in early treatment.
abstract: OBJECTIVE
  To evaluate the efficacy of amikacin on sputum conversion during initial sputum smear positive tuberculosis treatment.
  
  
  METHODS
  Single-center observational cohort study (2012-2013) evaluating time to sputum smear conversion with standard treatment (ST) versus standard treatment+amikacin (IV 15mg/kg/day) for seven days (STamK).
  
  
  RESULTS
  Forty-five patients were included. Median time to smear negative samples was 26.5 days (14-56) for the 30 (66.7%) patients included in the ST group and 48 days (19.5-69.5) for the 15 patients (33.3%) included in the STamK group (P=0.76). Time to negative culture was only known for 27 patients (61.4%): 47.5 days (26-58) for 18 patients in the ST group and 40 days (14-77) for nine patients in the STamK group.
  
  
  CONCLUSIONS
  Despite our small sample size, the addition of amikacin in active tuberculosis treatment did not seem to impact time to smear conversion or period of contagiousness.
authors.affiliation: CHU Avicenne, Service des maladies infectieuses et tropicales, 93000 Bobigny, France. Electronic address: frederic.mechai@avc.aphp.fr.
authors.forename: F
authors.initials: F
authors.lastname: Méchaï
authors.affiliation: CHU Avicenne, Service des maladies infectieuses et tropicales, 93000 Bobigny, France.
authors.forename: J
authors.initials: J
authors.lastname: Figoni
authors.affiliation: CHU Avicenne, Service des maladies infectieuses et tropicales, 93000 Bobigny, France.
authors.forename: C
authors.initials: C
authors.lastname: Leblanc
authors.affiliation: CHU Avicenne, Service des maladies infectieuses et tropicales, 93000 Bobigny, France.
authors.forename: M
authors.initials: M
authors.lastname: Gousseff
authors.affiliation: CHU Avicenne, Service des maladies infectieuses et tropicales, 93000 Bobigny, France.
authors.forename: N
authors.initials: N
authors.lastname: Vignier
authors.affiliation: CHU Avicenne, Service des maladies infectieuses et tropicales, 93000 Bobigny, France.
authors.forename: O
authors.initials: O
authors.lastname: Bouchaud
mesh_terms: D000328:Adult; D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D058491:Bacterial Load; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D010356:Patient Isolation; D013183:Sputum / Q000382:microbiology; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D000583:Amikacin
keywords: Amikacin; Amikacine; Isolation; Isolement; Tuberculose; Tuberculosis